Umbilical cord blood shows promise as cancer treatment
July 18, 1996
Web posted at: 1:45 a.m. EDT
From Correspondent Jeff Levine
PHILADELPHIA (CNN) -- Two new studies show umbilical cord
blood can be used to treat cancer, even when the substance
comes from an unrelated donor. The research raises hopes for
cord blood therapy in many diseases.
Transplanting blood obtained from the umbilical cord is still
a technique in its infancy. However the studies, reported in
the New England Journal of Medicine, show its promise.
"It would provide us with the ability to transplant many more
patients with cancer and immunodeficiency disorders," Dr.
Leslie Silberstein with the University of Pennsylvania said.
In one study, the patients were mostly children with a
variety of severe illnesses, including leukemia. In 25
patients, only two had a severe reaction to the transplant.
And that, in spite of the fact the blood was not a perfect
match to their immune systems.
In another case, a 26-year old woman with leukemia received a
cord blood transplant. Her treatment succeeded, even though
the donor wasn't a family member. Her case could help answer
the question of whether cord blood works in adults.
Cord blood is rich in stem cells, the building blocks of the
immune system and whole blood. Until now, they've generally
been extracted from bone marrow, but the process is painful
and expensive, and many times mismatches don't work.
"In our experience with stem cells derived from bone marrow,
very few mismatches are tolerable to the recipient,"
Ethical questions raised
Normally, cord blood is thrown away at birth. Now, doctors
are starting to freeze it for later use, such as a bone
marrow transplants. The experimental approach has been tried
about 200 times.
Research at the University of Pennsylvania and other centers
is encouraging. It shows cord blood transplants have great
potential, but there are ethical questions to be answered. A
key issue is confidentiality related to information obtained
from the blood sample.
"Cord blood leaves a footprint. If you have HIV, if you have
a genetic disease, if you have ... biological material that
tells you something about an infection or something that the
person's been exposed to, or their heredity," Arthur Caplan
of the University of Pennsylvania said. "Maybe they want
that information revealed; maybe they don't."
Another issue is whether companies should be allowed to
charge for collecting and storing cord blood to treat an
illness that might develop in the future.
"I think if you put companies into this area and you start
having them market, the danger is that they're going to prey
upon the fears of people," Caplan said.
But cord blood bankers see it differently. One proponent says
these studies show cord blood transplants have arrived as a
© 1996 Cable News Network, Inc.
All Rights Reserved.